Foxy-5 Clinical Trials

Size	Price	Qty
1mg	USD 147
5mg	USD 387

Clinical Trials

Multiple clinical trials sponsored exclusively by WntResearch AB evaluate Foxy-5 across Phase 1 and Phase 2 studies targeting advanced solid tumors, specifically metastatic breast, colorectal, and metastatic prostate cancers. Completed early-phase trials assessed the safety, pharmacokinetics, and pharmacodynamics of the compound. Additionally, Phase 2 clinical research has been initiated to evaluate Foxy-5 as a neo-adjuvant treatment specifically for patients with colon cancer.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03883802	UNKNOWN	Colon Cancer	WntResearch AB	2019-04-12	PHASE2
NCT02655952	COMPLETED	Metastatic Breast Cancer; Metastatic Colon Cancer; Metastatic Prostate Cancer	WntResearch AB	2016-04	PHASE1
NCT02655952	Completed	Metastatic Breast Cancer\|Metastatic Colon Cancer\|Metastatic Prostate Cancer	WntResearch AB	2016-04	Phase 1
NCT02020291	COMPLETED	Metastatic Breast Cancer; Colorectal Cancer; Prostate Cancer	WntResearch AB	2013-06	PHASE1
NCT02020291	Completed	Metastatic Breast Cancer\|Colorectal Cancer\|Prostate Cancer	WntResearch AB	2013-06	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-12-09)

Check the Foxy-5 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a Wnt-5a mimicking hexapeptide, Foxy-5 binds to WNT receptor complexes and activates non-canonical WNT signaling pathways, which disrupts the cytoskeletal dynamics required for cellular migration and invasion. This suppression of tumor cell dissemination provides the mechanistic basis for inhibiting cancer cell spread in clinical indications such as metastatic breast cancer, colorectal cancer, and prostate cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).